Therapeutic effects of sodium nitroprusside combined verapamil for no-reflow during percutaneous coronary intervention
10.3969/j.issn.1008-0074.2017.04.18
- VernacularTitle:硝普钠联合维拉帕米对冠状动脉介入术中无复流的效果
- Author:
Yingwen CHEN
;
Yunzhao HU
;
Yanxian WU
;
Wensheng LI
;
You YANG
;
Linlin MAI
;
Jiankai ZHONG
- Keywords:
Angioplasty,balloon,coronary;
Nitroprusside;
Verapamil
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2017;26(4):416-419
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore therapeutic effects of sodium nitroprusside (SNP) combined verapamil on no-reflow during percutaneous coronary intervention (PCI).Methods: A total of 106 patients, who suffered from no-reflow during PCI in our department from Jan 2011 to Dec 2013, were selected.According to random number table method, patients were divided into SNP group (n=55, received SNP based on routine treatment) and combined treatment group (n=51, received verapamil based on SNP group).Cardiac troponin I (cTnI) level before and 16h~18h after PCI, cardiac function indexes after 12-month follow-up, incidence of major adverse cardiovascular events (MACE) were measured and compared between two groups.Results: Compared with before PCI, there were significant rise in cTnI level in both groups on 16~18h after PCI, P=0.001 both;compared with SNP group, there were significant reductions in cTnI level [(1.31±0.44)μg/L vs.(0.11±0.02)μg/L] and percentage of cTnI>0.10μg/L (94.5% vs.54.9%) in combined treatment group, P=0.001 both.Compared with SNP group after 12 months, there was significant rise in left ventricular ejection fraction [(62.29±3.06)% vs.(65.65±3.94)%], and significant reductions in left ventricular end-diastolic dimension[(50.24±3.73)mm vs.(47.60±4.72)mm] and left ventricular end-systolic dimension [(33.29±2.11)mm vs.(31.00±4.33)mm] in combined treatment group, P<0.05 all.There were no significant adverse reactions during hospitalization and follow-up in both groups.Conclusion: When no-reflow occurs during PCI, intracoronary injection of SNP combined verapamil can improve cardiac function, and its safety is good, which is worth extending.
